BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1176 related articles for article (PubMed ID: 33790892)

  • 21. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
    Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF
    J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.
    Hartley GE; Edwards ESJ; Aui PM; Varese N; Stojanovic S; McMahon J; Peleg AY; Boo I; Drummer HE; Hogarth PM; O'Hehir RE; van Zelm MC
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33443036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
    Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
    Front Immunol; 2021; 12():723585. PubMed ID: 34489974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.
    Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F
    J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
    Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
    Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
    PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
    Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
    Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays.
    Shah J; Liu S; Potula HH; Bhargava P; Cruz I; Force D; Bazerbashi A; Ramasamy R
    BMC Infect Dis; 2021 Apr; 21(1):325. PubMed ID: 33827460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.
    Edlow AG; Li JZ; Collier AY; Atyeo C; James KE; Boatin AA; Gray KJ; Bordt EA; Shook LL; Yonker LM; Fasano A; Diouf K; Croul N; Devane S; Yockey LJ; Lima R; Shui J; Matute JD; Lerou PH; Akinwunmi BO; Schmidt A; Feldman J; Hauser BM; Caradonna TM; De la Flor D; D'Avino P; Regan J; Corry H; Coxen K; Fajnzylber J; Pepin D; Seaman MS; Barouch DH; Walker BD; Yu XG; Kaimal AJ; Roberts DJ; Alter G
    JAMA Netw Open; 2020 Dec; 3(12):e2030455. PubMed ID: 33351086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
    Schlesinger T; Weißbrich B; Wedekink F; Notz Q; Herrmann J; Krone M; Sitter M; Schmid B; Kredel M; Stumpner J; Dölken L; Wischhusen J; Kranke P; Meybohm P; Lotz C
    PLoS One; 2020; 15(11):e0242917. PubMed ID: 33232382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.